Free Cancer Report

Book Appointment with Dr K R Prasanna Kumar in Chennai

Dr K R Prasanna Kumar

Radiation Oncologist

12 Years Exp. Chennai

Squamous Cell Carcinoma of the Head and Neck

HCG Cancer Centre, Chennai

12 years of experience

MBBS, DNB

Chennai

About Dr K R Prasanna Kumar:

Dr K. R. Prasanna Kumar is a radiation oncologist. He completed his graduation at one of the most prestigious medical colleges in Madurai, Tamil Nadu and completed his DNB in Radiotherapy at a prestigious institute in Chennai. Dr Kumar has presented many posters at AROI conferences. He is well versed with high precision radiation therapies like - 3DCRT, IMRT, IGRT, X-knife SRS, CyberKnife SRS, SBRT, HDR Brachytherapy and is experienced in handling Oncentra, Eclipse, Multiplan, etc.

Education:

MBBS - Madurai Medical College, 2008 DNB - Radiotherapy - DNB board, New Delhi, 2013

Experience:

2014 - 2015 Registrar at Apollo Cancer Hospital 2015 - Present Junior Consultant at HCG Hospital

Memberships:

Association of Radiation Oncologists of India (AROI)

Areas of interest:

Lung Cancer, Gastrointestinal (GI) Cancer, Breast Cancer, Head And Neck Cancer.

Research publications:

Yokota, Tomoya & Bendell, Johanna & LoRusso, Patricia & Tsushima, Takahiro & Desai, Ved & Kenmotsu, Hirotsugu & Watanabe, Junichiro & Ono, Akira & Murugesan, Bhavani & Silva, Joseph & Naito, Tateaki & Greenberg, Jonathan & Wang, Yibin & Jikoh, Takahiro & Shiga, Ryota & Hyman, David & Ho, Alan & Spriggs, David & Gounder, Mrinal. (2018). Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. British Journal of Cancer. 118. https://doi.org/10.1038/s41416-018-0102-1 Bauer, Todd & Gounder, Mrinal & Weise, Amy & Schwartz, Gary & Carvajal, Richard & Zernovak, Oleg & Beck, Alida & Doyle, Jana & Mendell-Harary, Jeanne & Kochan, Jarema & Chen, Shuquan & LoRusso, Patricia & Tap, William & Somaiah, Neeta & Hyman, David & Meric-Bernstam, Funda & Hong, David. (2018). A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).. Journal of Clinical Oncology. 36. 11514-11514. https://doi.org/10.1200/JCO.2018.36.15_suppl.11514 Yokota, Tomoya & Bendell, Johanna & LoRusso, Patricia & Tsushima, Takahiro & Desai, Ved & Kenmotsu, Hirotsugu & Watanabe, Junichiro & Ono, Akira & Murugesan, Bhavani & Silva, Joseph & Naito, Tateaki & Greenberg, Jonathan & Wang, Yibin & Jikoh, Takahiro & Shiga, Ryota & Ho, Alan & Gounder, Mrinal. (2017). A call for global harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid tumors conducted in the United States and Japan.. Journal of Clinical Oncology. 35. 2536-2536. https://doi.org/10.1200/JCO.2017.35.15_suppl.2536 Dinardo, Courtney & Rosenthal, Joseph & Andreeff, Michael & Zernovak, Oleg & Gajee, Roohi & Chen, Shuquan & Rosen, Michael & Song, Saeheum & Kochan, Jarema & Limsakun, Tharin & Olin, Rebecca. (2016). Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results. Blood. 128. 593-593. https://doi.org/10.1182/blood.V128.22.593.593 Bauer, Todd & Hong, David & Somaiah, Neeta & Cai, Charles & Song, Saeheum & Gajee, Roohi & Rosen, Michael & Kochan, Jarema & Chen, Shuquan & Hyman, David & Masters, Tyler & Meric-Bernstam, Funda & Tse, Archie & LoRusso, Patricia & Weise, Amy & Gounder, Mrinal. (2015). Abstract B27: A phase I dose escalation study of the MDM2 inhibitor DS-3032b in patients with advanced solid tumors and lymphomas. Molecular Cancer Therapeutics. 14. B27-B27. https://doi.org/10.1158/1535-7163.TARG-15-B27 Gounder, Mrinal & Bauer, Todd & Schwartz, Gary & Masters, Tyler & Carvajal, Richard & Song, Saeheum & Gajee, Roohi & Zernovak, Oleg & Rosen, Michael & Kochan, Jarema & Chen, Shuquan & Hyman, David & Gokmen, Sugun & Meric-Bernstam, Funda & LoRusso, Patricia & Somaiah, Neeta & Weise, Amy & Hong, David. (2016). A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.. Journal of Clinical Oncology. 34. 2581-2581. https://doi.org/10.1200/JCO.2016.34.15_suppl.2581

Specialisation

Lung Cancer, Gastrointestinal (GI) Cancer, Breast Cancer, Head And Neck Cancer.